NIVELLES, Belgium – April 14, 2025

Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics, is proud to announce a research collaboration with the University of Arizona Health Sciences Center for Advanced Molecular and Immunological Therapies focused on the development of an mRNA-based neoantigen cancer vaccine platform. This joint project aims to demonstrate proof of concept for a novel approach to treating melanoma using cutting-edge RNA technology and predictive antigen science.

The partnership combines the University of Arizona Health Sciences’ expertise in neoantigen prediction with Quantoom’s proprietary RNA production and formulation platform.

The initial phase of the project will focus on a murine melanoma model. Center for Advanced Molecular and Immunological Therapies, or CAMI, researchers will identify and select neoantigens, which will be turned into mRNA drug products by Quantoom using its integrated Ntensify^® production platform and its Ncapsulate^® QCX RNA formulation chemistry. The vaccine candidates will then be evaluated in vivo by CAMI researchers to assess their immunogenicity and therapeutic potential.

“It is incredibly exciting to be working with such an innovative and experienced company like Quantoom on a technology that has shown early success and promise in its ability to change the future of cancer treatment,” said Ryan Sprissler, PhD, associate director for the Center for Advanced Molecular and Immunological Therapies at the U of A Health Sciences and associate research professor at the university’s BIO5 Institute.

“We’re thrilled to collaborate with the University of Arizona Health Sciences on this pioneering research,” added José Castillo, CEO of Quantoom Biosciences. “Our platform is uniquely positioned to accelerate the development of personalized cancer vaccines, and this project is a perfect example of how combining expertise can drive meaningful progress.”